The need to implement nonindustry COVID-19 clinical trials in non-high-income countries
Entity
UAM. Departamento de FarmacologíaPublisher
The International Society of Global Health (ISoGH)Date
2020-05-15Citation
10.7189/jogh.10.010351
J Glob Health 10.1 (2020): 010351
ISSN
2047-2986DOI
10.7189/jogh.10.010351Editor's Version
http://doi.org/10.7189/jogh.10.010351Subjects
COVID-19; clinical trials; non-high-income countries; generic medicines; Farmacia; MedicinaNote
The online version of this article contains supplementary materialRights
© 2020 The Author(s)Files in this item
Google Scholar:Dal-Ré, Rafael
-
Carcas Sansuán, Antonio Javier
-
Sreeharan, Nadarajah
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial
García García, Irene; Rodríguez-Rubio, Miguel; Rodríguez Mariblanca, Amelia; Martínez de Soto, Lucía; Díaz García, Lucía; Monserrat Villatoro, Jaime; Queiruga Parada, Javier; Seco Meseguer, Enrique; Rosales, María J.; González, Juan; Arribas, José R.; Carcas Sansuán, Antonio Javier; Oliva Senovilla, Pedro de la; Borobia Pérez, Alberto M.
2020-06-03